Abstract: Objective To investigate the role of linezolid in the treatment of severe multidrug-resistant tuberculosis, especially the pre-XDR-TB and XDR-TB. Methods 9 patients with pre-XDR-TB and 3 patients with XDR-TB were collected from the tuberculosis clinic of Shenzhen Center for Chronic Disease Control from July 1, 2015 to June 30, 2017. The demographic characteristics and disease characteristics were summarized. After consultation with specialists in the departments, the individualized treatment plan containing linezolid was formulated. During the treatment, the treatment plan was adjusted according to the Results of drug sensitivity and adverse reactions, and the clinical efficacy and drugs adverse reactions were observed. Results 10 were cured and 2 failed. The success rate of treatment was 83.3% (10/12). 8 of the 12 patients had adverse reactions, including 3 cases of optic nerve injury. The visual acuity was restored after discontinuation of linezolid. One case had mild anemia and 3 cases had leukopenia, which returned to normal after symptomatic treatment. There were 7 cases of liver function damage, of which 5 cases needed to stop medication for a short time and change the treatment plan, and then completed the treatment smoothly. Conclusion Linezolid is effective in the treatment of severe MDR-TB, with controlled side effects and it is worth promotion.

Key words: Linezolid, Multidrug-resistant tuberculosis, pre-XDR-TB, XDR-TB, Drugs adverse reaction